Given its role in the maintenance of genome stability, the synergy with KRAS mutations, and the clinical significance of altered expression, we propose that deficiencies in STAG2 represent a potential therapeutic vulnerability that can be exploited for improved treatment and possible prevention of PDA. Here, KRAS is linked to Patent ductus arteriosus.